Investigational Drug Information for D-Tryptophan
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug D-Tryptophan?
D-Tryptophan is an investigational drug.
There have been 18 clinical trials for D-Tryptophan.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 17th 2003.
The most common disease conditions in clinical trials are Breast Neoplasms, Prostatic Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), NewLink Genetics Corporation, and NRG Oncology.
Summary for D-Tryptophan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,985 |
| WIPO Patent Applications | 1,428 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 2 (2003-12-17) |
| Vendors | 101 |
Recent Clinical Trials for D-Tryptophan
| Title | Sponsor | Phase |
|---|---|---|
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | National Cancer Institute (NCI) | Phase 3 |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | NRG Oncology | Phase 3 |
| Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | Advanced Accelerator Applications | Phase 1 |
Clinical Trial Summary for D-Tryptophan
Top disease conditions for D-Tryptophan
Top clinical trial sponsors for D-Tryptophan
US Patents for D-Tryptophan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
